DIA’s India Annual Meeting to host discussions on evolving regulatory landscape DIA global organisation of life sciences professionals, will facilitate a series of discussions on the evolving regulatory landscape in India, the transformative power of digitisation in healthcare, and how to prioritise patient safety during the DIA India Annual Meeting, which will be held September 24 and 25 at Novotel Mumbai. This year’s theme, “Confluence of Care,” focuses on the need for widespread cooperation and deliberation to drive the safe and effective implementation of emerging treatments. For the first time, attendees of the India Annual Meeting can choose from three specialised tracks — pharmacovigilance, clinical-regulatory, and medical devices. “The future of healthcare in India hinges on two critical factors: access and safety,” said Dr Ashok Swain, General Manager, India Operations, DIA.

The DIA India Annual Meeting is back and it's bigger and better than ever before! This year's event features a diverse array of tracks including Pharmacovigilance (PV), Clinical Innovations, Regulatory Sciences, and Medical Devices, each offering new and interesting topics. Whether you're looking to deepen your expertise, stay up to date with the latest industry trends, or network with professionals, there's something for everyone. Don’t miss this opportunity to enhance your knowledge and connect with industry leaders! #DIA #Pharmacovigilance #MedicalDevices #Clinical #RegulatoryAffairs #MedicoLegal #GenerativeAI #PatientSafety

The #agreement aims to promote the exchange of information and collaboration in areas related to medical products, as well as administrative and regulatory matters within the jurisdictions of both parties. Government of India #healthcare #PharmaIndustrialIndia

As we increasing news on the launch of Vonoprazan in Indian Markets. Pronto Consult did a Quick fire survey amongst the Doctors related to this molecule. 1. 77% of the HCPs were aware about this molecule either through news or have seen on the social media including Linkedin, launches in the nearby country markets. 2. There is definitely a willingness to prescribe and look at the advantages of this molecule. 3. Approval by USFDA has been the highlight for this molecule in end of 2023 4. Some the Doctors when they travelled abroad in the last few months, have tried the Molecule as they have been experiencing the symptoms and have found satisfactory results. 5. Pronto Consult understands that the first mover advantage would add significant value to the companies who launch the same at a acceptable price point, however price currently may not be very significant. Write to us to know more and add significant value to your launches and market strategy inputs #vonoprazan #PPIs #acidreflux #indianpharmaindustry #newlaunch #usfda #marketentry #consumers #patients #doctors #antiulcermarket #india #data #perceptions #USA #Japan #uaehealthcare #nepalhealthcare #bangladeshhealthcare #prontoconsult #newlaunch #pricepoint Dr. Karishma Shah Dr Hari Natarajan

As we increasing news on the launch of Vonoprazan in Indian Markets. Pronto Consult did a Quick fire survey amongst the Doctors related to this molecule. 1. 77% of the HCPs were aware about this molecule either through news or have seen on the social media including Linkedin, launches in the nearby country markets. 2. There is definitely a willingness to prescribe and look at the advantages of this molecule. 3. Approval by USFDA has been the highlight for this molecule in end of 2023 4. Some the Doctors when they travelled abroad in the last few months, have tried the Molecule as they have been experiencing the symptoms and have found satisfactory results. 5. Pronto Consult understands that the first mover advantage would add significant value to the companies who launch the same at a acceptable price point, however price currently may not be very significant. Write to us to know more and add significant value to your launches and market strategy inputs #vonoprazan #PPIs #acidreflux #indianpharmaindustry #newlaunch #usfda #marketentry #consumers #patients #doctors #antiulcermarket #india #data #perceptions #USA #Japan #uaehealthcare #nepalhealthcare #bangladeshhealthcare #prontoconsult #newlaunch #pricepoint Dr. Karishma Shah Dr Hari Natarajan

What is required to Get Your Clinical Trial Application Approved in India Required: Your Key to Navigating India's Clinical Trial Approval! 🌟 Unlock Success and Accelerate clinical Research Excellence. ✔ Understand Regulatory Requirement ✔ Prepare Comprehensive Documentation ✔ Engage with Ethical Committees ✔ Demonstrate Robust Study Design ✔ Showcase Investigator Qualifications Read more- https://lnkd.in/dRUfJ6bP 🌐 Follow ProRelix Research: For a continuous stream of exciting developments, informative slides, and expert insights in the dynamic world of Clinical Research! 🌐 📊 #clinicaltrialsindia #clinicalresearch #drugapproval #pharmaregulation #indianhealthcare #medicalresearch #FDAIndia #drugdevelopment #healthcareregulation #clinicaltrialapproval #pharmaindustry #healthcarepolicy #regulatoryaffairs #drugsafety #biomedicalresearch

Big news for Indian patients! 🇮🇳 India just waved goodbye to clinical trials for some drugs already approved in developed countries like the US, UK, and EU. This could mean faster access to life-saving meds! #India #healthcare #clinicaltrials #drugs #medicalscience

Only 3 DAYS TO GO for the 2nd Annual Summit on Medical Affairs, India Chapter! A warm welcome to all the 150+ delegates joining us. Your presence is key in ensuring the success of this event. We look forward to seeing you on 9th February 2024 for a day full of insightful sessions and collaborative learning! #asma #medicalaffairs #medicalconference #medicalevents #pharma #india #continuouslearning #digital #medicalconference #bestpractices

Join our distinguished leaders for a panel discussion on 'A Multi-Stakeholder Perspective on Integrating Clinical Research into the Continuum of Care.' Don't miss this pivotal discussion at #ETCREC. Key Takeaways: SUNEELA THATTE, VP and head Healthcare R&D India, Merck Group "Clinical research is that science which is societal in nature." "Today no clinical trial happens without technology." Dr Avinash Ramchandra Kakade MBBS, MPhil, PMP®, FRSPH (UK), Sr Vice President Global Head of Pharmacovigilance, Dr. Reddy's Laboratories "Things change drastically once the drug is in the market." "Big thrust happens after a drug is commercialized." Dr. Shubhadeep D Sinha, Sinha, Senior Vice President & Head (Global) - Clinical Development & Medical Affairs, HETERO LABS LIMITED - India "Clinical trials and product development is a journey from sponsor lab to patient." Moderator: Dr. Jaideep Gogtay, Chief Medical Officer, Cipla Know More: https://bit.ly/48cQUGd #ETCREC #ResearchExcellence #HealthcareInnovation #MedicalConference #ClinicalTrials #HealthScience #ScienceCommunity #ResearchCommunity

PM-STIAC meeting deliberates robust regulatory ecosystem for medical products in India The meeting brought together PM-STIAC members, key government officials, and experts from the medical and health industry to discuss priority areas of the health products ecosystem, particularly the current regulatory processes of medical products, gaps, and challenges faced by stakeholders, and emerging opportunities in the regulatory space. The aim was to provide recommendations for a robust regulatory ecosystem. #PMSTIAC | #robustregulatoryecosystem | #medicalproducts | #governmentofficials | #Healthnews Read more: